LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

Accueil・Liste d'Actions・Johnson and Johnson

Johnson and Johnson

Fermé

Secteur Soins de santé

160.15 -0.86

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

160.04

Max

162.15

Chiffres clés
By Trading Economics
Revenu	-2B 2.7B
Ventes	50M 23B
P/E Moyenne du Secteur	21.72 112.16
BPA	2.42
Marge bénéficiaire	11.973
Employés	131,900
EBITDA	2.1B 7.8B

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+10.43 upside

Dividendes
By Dow Jones
Prochains Résultats	21 janv. 2025
Date du Prochain Dividende	10 déc. 2024
Date du Prochain Détachement de Dividende	26 nov. 2024

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	6.6B 396B
Ouverture précédente	161.01
Clôture précédente	160.15

Sentiment de l'Actualité

By Acuity

28%

72%

87 / 389 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

160.9 / 164.1 Support & Résistance

Johnson and Johnson Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

28 oct. 2024, 16:07 UTC

Acquisitions, Fusions, Rachats

AbbVie to Acquire Aliada Therapeutics for $1.4 Billion -- Update

15 oct. 2024, 19:26 UTC

Résultats

Trending: Johnson & Johnson Posts Higher-Than-Expected Sales

21 oct. 2024, 15:26 UTC

Acquisitions, Fusions, Rachats

Starboard Value Buys Into Dow Jones Spinoff; Elf Beauty Rallies -- IBD

21 oct. 2024, 09:51 UTC

Actualités

Starboard Targets Another Health Company. Why Kenvue Is in Its Sights. -- Barrons.com

21 oct. 2024, 09:30 UTC

Actualités

J&J's Ketamine-Derived Drug Is Taking Off -- WSJ

15 oct. 2024, 12:09 UTC

Actualités

Résultats

J&J Reports Strong Earnings but Talc Worries Remain. The Stock Falls. -- Barrons.com

15 oct. 2024, 12:04 UTC

Résultats

Johnson & Johnson Earnings Top; Dow Giant Falls Amid Lowered Outlook -- IBD

15 oct. 2024, 11:52 UTC

Actualités

Résultats

J&J Reports Strong Earnings but Talc Worries Remain. The Stock Falls. -- Barrons.com

15 oct. 2024, 10:50 UTC

Résultats

Johnson & Johnson Stock Rises On Q3 Sales Beat And Guidance Raise -- MarketWatch

15 oct. 2024, 10:28 UTC

Actualités

Résultats

J&J Reports Strong Earnings but Talc Worries Remain. The Stock Rises. -- Barrons.com

15 oct. 2024, 10:25 UTC

Résultats

J&J Reports Strong Earnings but Talc Worries Remain -- Barrons.com

15 oct. 2024, 10:20 UTC

Résultats

J&J Earnings Beat Expectations, Aided by Prescription-Drug Sales -- WSJ

15 oct. 2024, 10:20 UTC

Résultats

Johnson & Johnson Cuts 2024 View To Adj EPS $9.88-Adj EPS $9.98 Vs Prior View $9.97-$10.07 >JNJ

15 oct. 2024, 10:20 UTC

Résultats

Johnson & Johnson Cuts 2024 Adjusted Operational EPS View to $9.86-$9.96 Vs Prior View $10.00-$10.10 >JNJ

15 oct. 2024, 10:20 UTC

Résultats

Johnson & Johnson Raises 2024 Adjusted Operational Sales Growth View to 5.7%-6.2% From Prior View 5.5%-6%>JNJ

15 oct. 2024, 10:20 UTC

Résultats

Johnson & Johnson Updates 2024 Guidance to Reflect Improved Perfromance and Impact From Recent Acquisition of V-Wave >JNJ

15 oct. 2024, 10:20 UTC

Résultats

Johnson & Johnson 3Q U.S. Sales $12.91B >JNJ

15 oct. 2024, 10:20 UTC

Résultats

Johnson & Johnson Raises 2024 Operational Sales View to $89.4B-$89.8B Vs Prior View $89.2B-$89.6B >JNJ

15 oct. 2024, 10:20 UTC

Résultats

Johnson & Johnson: MedTech Business, With Addition of Shockwave Medical, Delivered Operational Sales Growth of 6.4% in 3Q >JNJ

15 oct. 2024, 10:20 UTC

Résultats

Johnson & Johnson Raises 2024 View To Sales $88.4B-$88.8B Vs Prior View $88.0B-$88.4B >JNJ

15 oct. 2024, 10:20 UTC

Résultats

Johnson & Johnson 3Q Adj EPS $2.42 >JNJ

15 oct. 2024, 10:20 UTC

Résultats

Johnson & Johnson: Innovative Medicine 3Q Results Driven by Key Brands Such as DARZALEX, ERLEADA, TREMFYA and SPRAVATO and Continued Uptake From Recently Launched Products Including CARVYKTI, RYBREVANT, TECVAYLI and TALVEY, With 11 Assets Delivering Double-Digit Growth >JNJ

15 oct. 2024, 10:20 UTC

Résultats

Johnson & Johnson 3Q Orthopaedics Sales $2.19B >JNJ

15 oct. 2024, 10:20 UTC

Résultats

Johnson & Johnson 3Q International Sales $9.56B >JNJ

15 oct. 2024, 10:20 UTC

Résultats

Johnson & Johnson 3Q Worldwide MedTech Sales $7.89B >JNJ

15 oct. 2024, 10:20 UTC

Résultats

Johnson & Johnson 3Q Worldwide Innovative Medicine Sales $14.58B >JNJ

15 oct. 2024, 10:20 UTC

Résultats

Johnson & Johnson 3Q Sales $22.47B >JNJ

15 oct. 2024, 10:20 UTC

Résultats

Johnson & Johnson 3Q EPS $1.11 >JNJ

15 oct. 2024, 10:20 UTC

Résultats

Johnson & Johnson 3Q Worldwide MedTech Sales $7.89B >JNJ

15 oct. 2024, 10:20 UTC

Résultats

Johnson & Johnson 3Q Orthopaedics Sales $2.19B >JNJ

Comparaison

Variation de prix

Johnson and Johnson prévision

Objectif de Prix

By TipRanks

10.43% hausse

Prévisions sur 12 Mois

Moyen 178.45 USD 10.43%

Haut 215 USD

Bas 159 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

12 ratings

Achat

Maintien

Vente

Basé sur 12 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

160.9 / 164.1Support & Résistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

87 / 389Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Johnson and Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopedic, surgery, and vision fields.